Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

In a new publication, researchers from the German Center for Diabetes Research (DZD) and the University of Medicine ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

The placebo-controlled, double-blind, randomised Phase I trial involved 100 healthy participants.

Licensed scientific and clinical intelligence integrated into the 3RnD platform to support AI-Driven Discovery and ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027. Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be rep ...

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...

New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...

New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial ...

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...

From Science.org. "T3D Therapeutics alleges that contract researchers delivered “medically impossible” results on its candidate drug. In 2023, the drug ...